MEDELPHARM
March 23, 2021
Reducing “time to market” is the ultimate goal
for every pharmaceutical lab. Being the first on
the market brings a competitive advantage for
prescription, over-the-counter, or generic-drug
manufacturers. Applying quality-by-design
(QbD) principles at the formulation phase can
prevent tablet defects at an early stage and
thereby drastically reduce time during the
complex and troublesome phase of “scale-up”.
www.pharmaphorum.com
March 3, 2021
UCB's announced a new partnership in order to integrate IA technologies as a tool for its development.The aim is to "significantly accelerate the iteration cycles required to identify more effective molecules".
The complete Press article can be found here.